<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816582</url>
  </required_header>
  <id_info>
    <org_study_id>PET/CT Breast</org_study_id>
    <nct_id>NCT00816582</nct_id>
  </id_info>
  <brief_title>PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:&#xD;
&#xD;
      To determine whether [18F]FES can predict clinical benefit (defined as complete response,&#xD;
      partial response and stable disease ≥ 6 months) to fulvestrant (250 mg IM q 28 days) in&#xD;
      post-menopausal women with recurrent or metastatic ER+ breast cancer who are candidates for&#xD;
      further hormonal therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The majority of women diagnosed with breast cancer are post-menopausal, of which up to 75%&#xD;
      are estrogen (ER) and/or progesterone receptor (PR) positive. Even in pre-menopausal breast&#xD;
      cancer over half of all patients will have expression of these hormone receptors. Thus&#xD;
      therapeutic strategies targeting the estrogen receptor or its ligand are the most common&#xD;
      treatment offered in breast cancer. Despite substantial benefits now demonstrated with&#xD;
      selective estrogen receptor modulators (e.g. tamoxifen) and aromatase inhibitors (e.g.&#xD;
      anastrazole, letrozole and exemestane), a significant proportion of patients will still&#xD;
      unfortunately have or develop resistance to these hormonal therapies.&#xD;
&#xD;
      Despite approximately two-thirds of patients who are prescribed fulvestrant following prior&#xD;
      hormonal agents not benefiting from this therapy, clinicians are still offering this option&#xD;
      to all suitable women because of the lack of a better means of identifying the individual&#xD;
      responders.&#xD;
&#xD;
      To assess whether the recommended treatment is beneficial to a specific individual, the&#xD;
      disease burden is assessed before and following treatment. Conventional imaging techniques&#xD;
      such as the bone scan or computerized tomography (CT) can take several months to show a&#xD;
      successful response to treatment. Positron emission tomography (PET) can improve the&#xD;
      evaluation of women with breast cancer by providing an accurate assessment of the extent of&#xD;
      disease and unique information about tumor biology such as metabolic activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">November 30, 2010</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">September 17, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>CBR is defined as a patient having a best overall response of a complete response (CR), partial response (PR), or stable disease for at least 24 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PET/CT Guided FES Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline</intervention_name>
    <description>A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.</description>
    <arm_group_label>PET/CT Guided FES Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic Imaging: 18F-FES PET/CT - Baseline</intervention_name>
    <description>A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.</description>
    <arm_group_label>PET/CT Guided FES Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up</intervention_name>
    <description>A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.</description>
    <arm_group_label>PET/CT Guided FES Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for &gt; 12 months or&#xD;
             follicle stimulating hormone and estrogen levels within post-menopausal range, or&#xD;
             prior bilateral oophorectomy)&#xD;
&#xD;
          -  hormone receptor positive (ER and/or PgR) disease as determined locally&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  life expectancy of ≥ 3 months&#xD;
&#xD;
          -  the presence of at least one measurable or evaluable (non-measurable) lesion&#xD;
&#xD;
          -  informed consent prior to any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life threatening metastatic visceral disease&#xD;
&#xD;
          -  brain or leptomeningeal metastases&#xD;
&#xD;
          -  prior exposure to fulvestrant&#xD;
&#xD;
          -  history of bleeding diathesis or need for long term anti-coagulation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Chia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Cancer Agency - Vancouver Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Fraser Valley</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Island</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-menopausal hormone receptor positive recurrent/metastatic breast cancer.</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Recurrent or metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

